1.
Semin Radiat Oncol
; 31(3): 217-226, 2021 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34090648
RESUMO
Metastatic cancer is inherently heterogeneous, and patients with metastatic disease can experience vastly different oncologic outcomes depending on several patient- and disease-specific characteristics. Designing trials for such a diverse population is challenging yet necessary to improve treatment outcomes for metastatic-previously thought to be incurable-disease. Here we review core considerations for designing and conducting clinical trials involving radiation therapy and immunotherapy for patients with metastatic cancer.